Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch

Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer. Clin Cancer Res; 21(20); 4505–7. ©2015 AACR. See related article by Cui et al., p. 4619